메뉴 건너뛰기
Annals of Neurology
Volumn 68, Issue 3, 2010, Pages 395-399
Natalizumab dosage suspension: Are we helping or hurting?
Author keywords

[No Author keywords available]
Indexed keywords

NATALIZUMAB; ALPHA4 INTEGRIN; MONOCLONAL ANTIBODY;
EID: 77956388036     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.22163     Document Type: Article
Times cited : (111)
References (9)
  • 1
    • 33644584352 scopus 로고    scopus 로고
    • A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
    • AFFIRM Investigators
    • Polman CH, O'Connor PW, Havrdova E, et al; AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910.
    • (2006) N Engl J Med , vol.354 , pp. 899-910
    • Polman, C.H.1    O'Connor, P.W.2    Havrdova, E.3
  • 2
    • 33644608613 scopus 로고    scopus 로고
    • Natalizumab plus interferon beta-1a for relapsing multiple sclerosis
    • SENTINEL Investigators
    • Rudick RA, Stuart WH, Calabresi PA, et al; SENTINEL Investigators. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006;354:911-923.
    • (2006) N Engl J Med , vol.354 , pp. 911-923
    • Rudick, R.A.1    Stuart, W.H.2    Calabresi, P.A.3
  • 3
    • 77949279537 scopus 로고    scopus 로고
    • Natalizumab associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: Lessons from 28 cases
    • Clifford D, Luca A, Simpson DM, et al. Natalizumab associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 2010;9:438-446.
    • (2010) Lancet Neurol , vol.9 , pp. 438-446
    • Clifford, D.1    Luca, A.2    Simpson, D.M.3
  • 4
    • 57149117126 scopus 로고    scopus 로고
    • New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab
    • Hartung HP. New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab. Lancet Neurol 2009;8:28-31.
    • (2009) Lancet Neurol , vol.8 , pp. 28-31
    • Hartung, H.P.1
  • 6
    • 3042753418 scopus 로고    scopus 로고
    • Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis
    • Dalton CM, Miszkiel KA, Barker GJ, et al. Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis. J Neurol 2004;251:407-413.
    • (2004) J Neurol , vol.251 , pp. 407-413
    • Dalton, C.M.1    Miszkiel, K.A.2    Barker, G.J.3
  • 7
    • 61549088471 scopus 로고    scopus 로고
    • Immunologic and clinical status 14 months after cessation of natalizumab therapy
    • Stüve O, Cravens PD, Frohman EM, et al. Immunologic and clinical status 14 months after cessation of natalizumab therapy. Neurology 2009;72:396-401.
    • (2009) Neurology , vol.72 , pp. 396-401
    • Stüve, O.1    Cravens, P.D.2    Frohman, E.M.3
  • 8
    • 41549130359 scopus 로고    scopus 로고
    • Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients
    • DOI 10.1212/01.wnl.0000265393.03231.e5, PII 0000611420080325100002
    • Vellinga MM, Castelijns JA, Barkhof F, et al. Postwithdrawal rebound increase T2 lesional activity in natalizumab-treated MS patients. Neurology 2008;70(13 pt 2);1150-1151. (Pubitemid 351464749)
    • (2008) Neurology , vol.70 , Issue.13 PART 2 , pp. 1150-1151
    • Vellinga, M.M.1    Castelijns, J.A.2    Barkhof, F.3    Uitdehaag, B.M.J.4    Polman, C.H.5
  • 9
    • 77956385153 scopus 로고    scopus 로고
    • Natalizumab drug holiday in MS: Poorly tolerated
    • Killestein J, Vennegoor A, Strijbis E, et al. Natalizumab drug holiday in MS: poorly tolerated. Ann Neurol 2010;68:392-395.
    • (2010) Ann Neurol , vol.68 , pp. 392-395
    • Killestein, J.1    Vennegoor, A.2    Strijbis, E.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.